Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages

  van Gennip, Maria ^a,b   Moser, Claus ^a   Christensen, Louise D ^b   Bjarnsholt, Thomas ^a,b   Calum, Henrik ^a   Jensen, Peter Ø ^a   Christophersen, Lars ^a   Hougen, Hans Petter ^b   Ciofu, Oana ^b   Molin, Søren ^c   Givskov, Michael ^b   Høiby, Niels ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Cystic fibrosis; G CSF; MIP 2; Tobramycin

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; TOBRAMYCIN; ANTIINFECTIVE AGENT; CXCL2 CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL IMMUNITY; BACTERIAL STRAIN; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; FIRST PASS EFFECT; HISTOPATHOLOGY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; ANIMAL; BACTERIAL PNEUMONIA; BAGG ALBINO MOUSE; CYSTIC FIBROSIS; DISEASE MODEL; DRUG EFFECT; HOSPITALIZATION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; PATHOLOGY; PSEUDOMONAS INFECTION; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMOKINE CXCL2; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG; MICE; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOBRAMYCIN;

EID: 76249087236     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp352     Document Type: Article

References (62)

1. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065-9.
2. Høiby N. P. aeruginosa in Cystic Fibrosis Patients Resists Host Defenses, Antibiotics. Microbe Magazine 2006; 571-7.
3. Breitenstein S, Walter S, Bosshammer J et al. Direct sputum analysis of Pseudomonas aeruginosa macrorestriction fragment genotypes in patients with cystic fibrosis. Med Microbiol Immunol 1997; 186: 93-9.
4. Thomassen MJ, Demko CA, Boxerbaum B et al. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979; 140: 873-80.
5. Li Z, Kosorok MR, Farrell PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581-8.
6. Kosorok MR, Zeng L, West SE et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32: 277-87.
7. Emerson J, Rosenfeld M, McNamara S et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
8. Martin DW, Schurr MJ, Mudd MH et al. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 1993; 90: 8377-81.
9. Boucher JC, Yu H, Mudd MH et al. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 1997; 65: 3838-46.
10. Mathee K, Ciofu O, Sternberg C et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145: 1349-57.
11. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4: 49-54.
12. Govan JR, Doherty C, Glass S. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection 1987; 15: 300-7.
13. Hassett DJ, Cuppoletti J, Trapnell B et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002; 54: 1425-43.
14. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-61.
15. Taccetti G, Campana S, Festini F et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-61.
16. Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-4.
17. Littlewood JM, Miller MG, Ghoneim AT et al. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985; 325: 865.
18. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5.
19. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338: 725-6.
20. Douglas TA, Brennan S, Gard S et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33: 305-11.
21. Gibson RL, Emerson J, Mayer-Hamblett N et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42: 610-23.
22. Frederiksen B, Lanng S, Koch C et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21: 153-8.
23. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999; 28: 159-66.
24. Hansen CR, Pressler T, Koch C et al. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005; 4: 35-40.
25. Govan JR, Nelson JW. Microbiology of cystic fibrosis lung infection: themes and issues. J R Soc Med 1993; 86: 11-8.
26. Høiby N, Friis B, Jensen K et al. Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatr Scand Suppl 1982; 301: 75-100.
27. Martin AJ, Smalley CA, George RH et al. Gentamicin and tobramycin compared in the treatment of mucoid Pseudomonas lung infections in cystic fibrosis. Arch Dis Child 1980; 55: 604-7.
28. Moser C, van Gennip M, Bjarnsholt T et al. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS 2009; 117: 95-107.
29. Lee B, Haagensen JA, Ciofu O et al. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 2005; 43: 5247-55.
30. Bartels H. Metabolic rate of mammals equals the 0.75 power of their body weight. Expl Biol Med 1982; 7: 1-11.
31. Pedersen SS, Shand GH, Hansen BL et al. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS 1990; 98: 203-11.
32. Moser C, Johansen HK, Song Z et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 1997; 105: 838-42.
33. Høiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand B Microbiol Immunol 1974; 82: 541-50.
34. Moser C, Jensen PO, Kobayashi O et al. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol 2002; 127: 206-13.
35. Johansen HK, Espersen F, Cryz SJ Jr et al. Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun 1994; 62: 3146-55.
36. Hentzer M, Teitzel GM, Balzer GJ et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001; 183: 5395-401.
37. Anwar H, Costerton JW. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990; 34: 1666-71.
38. Anwar H, Strap JL, Costerton JW. Susceptibility of biofilm cells of Pseudomonas aeruginosa to bactericidal actions of whole blood and serum. FEMS Microbiol Lett 1992; 71: 235-41.
39. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-49.
40. Saba S, Soong G, Greenberg S et al. Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways. Am J Respir Cell Mol Biol 2002; 27: 561-7.
41. Standiford TJ, Kunkel SL, Greenberger MJ et al. Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996; 59: 24-8.
42. Gregory AD, Hogue LA, Ferkol TW et al. Regulation of systemic and local neutrophil responses by G-CSF during pulmonary Pseudomonas aeruginosa infection. Blood 2007; 109: 3235-43.
43. Jensen PO, Moser C, Kharazmi A et al. Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. J Cyst Fibros 2006; 5: 145-51.
44. Govan JR, Fyfe JA. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother 1978; 4: 233-40.
45. Govan JR. Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production. J Med Microbiol 1975; 8: 513-22.
46. Kelly NM, Rawling EG, Hancock RE. Determinants of the efficacy of tobramycin therapy against isogenic nonmucoid and mucoid derivatives of Pseudomonas aeruginosa PAO1 growing in peritoneal chambers in mice. Antimicrob Agents Chemother 1989; 33: 1207-11.
47. Ciofu O, Fussing V, Bagge N et al. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, β-lactamase activity and RiboPrinting. J Antimicrob Chemother 2001; 48: 391-6.
48. Zierdt CH, Schmidt PJ. Dissociation in Pseudomonas aeruginosa. J Bacteriol 1964; 87: 1003-10.
49. Irvin RT, Govan JW, Fyfe JA et al. Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins. Antimicrob Agents Chemother 1981; 19: 1056-63.
50. Markowitz SM, Macrina FL, Phibbs PV Jr. Antimicrobial susceptibility of mucoid Pseudomonas aeruginosa and their spontaneously occurring non-mucoid derivatives. J Antimicrob Chemother 1980; 6: 251-60.
51. Ciofu O, Riis B, Pressler T et al. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005; 49: 2276-82.
52. Oliver A, Canton R, Campo P et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-4.
53. Moyano AJ, Lujan AM, Argarana CE et al. MutS deficiency and activity of the error-prone DNA polymerase IV are crucial for determining mucA as the main target for mucoid conversion in Pseudomonas aeruginosa. Mol Microbiol 2007; 64: 547-59.
54. Lujan AM, Moyano AJ, Segura I et al. Quorum-sensing-deficient (lasR) mutants emerge at high frequency from a Pseudomonas aeruginosa mutS strain. Microbiology 2007; 153: 225-37.
55. Hoffman LR, Kulasekara HD, Emerson J et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 2009; 8: 66-70.
56. Köhler T, Buckling A, van Delden C. Cooperation and virulence of clinical Pseudomonas aeruginosa populations. Proc Natl Acad Sci USA 2009; 106: 6339-44.
57. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103: 8487-92.
58. Walter S, Gudowius P, Bosshammer J et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 1997; 52: 318-21.
59. Mainz JG, Naehrlich L, Schien M et al. Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax 2009; 64: 535-40.
60. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-30.
61. Wiesemann HG, Steinkamp G, Ratjen F et al. Placebocontrolled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88-92.
62. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for antiinfective drugs: an update. J Antimicrob Chemother 2005; 55: 601 7.